More stories

  • in

    Japan bucks private equity slowdown in Asia Pacific with deal value soaring 183% last year

    In 2023, the total deal value for the Asia Pacific region declined more than 23% to $147 billion from a year earlier, Bain & Company said in its report.
    Japan though, was an outlier with deal value surging 183% in 2023 from a year earlier, making it the largest private equity market in Asia Pacific for the first time, according to the report.
    Exits plunged 26% to $101 billion in 2023 from a year earlier — 40% of these exits were via initial public offerings, Bain said.

    An editorial picture of the Japan flag set against an economic trend graph and images associated with the stock market, finance and digital technology.
    Manassanant Pamai | Istock | Getty Images

    The total value of private equity deals in Asia Pacific last year fell to its lowest since 2014 as fundraising dropped to a 10-year low amid slowing growth, high interest rates and volatile public markets, according to management consultancy Bain & Company.
    Japan though, was an outlier, with deal value jumping 183% in 2023 from a year earlier, making it the largest private equity market in Asia Pacific for the first time, according to Bain’s 2024 Asia-Pacific Private Equity Report released Monday.

    Japan is an attractive investment due to its deep pool of target companies with “significant pool for performance improvements” and corporate governance reform pressure on Japan Inc to dispose of non-core assets, Bain said.
    Overall, deal value in the Asia-Pacific region declined more than 23% to $147 billion from a year earlier. This is also 35% below the 2018-2022 average value — a pace of decline that’s consistent with the global slowdown — and nearly 60% lower than the $359 billion peak in 2021, Bain said.
    Exits plunged 26% to $101 billion in 2023 from a year ago — of which 40% were via initial public offerings. Greater China accounted for 89% of the IPO exit value in Asia Pacific, with a vast majority listing in Shanghai and Shenzhen. Excluding Greater China IPOs, the total Asia-Pacific exit value was $65 billion.

    Stock picks and investing trends from CNBC Pro:

    “The outlook for exits in 2024 remains uncertain, but successful funds are not waiting for markets to bounce back. They are paving the way for sales that meet their target returns by using strategy reviews to highlight the potential value of deals to buyers,” Lachlan McMurdo, co-author of the firm’s annual report said in a statement.
    “This approach can reduce the inventory of aging assets and return cash to limited partners through 2024, even if the overall exit market remains depressed,” he added.

    Bain said many leading private equity funds have turned to exploring alternative asset classes, such as infrastructure operations with medium to high returns including renewable energy storage and data centers and airports.
    Here are some highlights of the report:

    Buyouts constituted 48% of total deal value in Asia Pacific last year, exceeding the value of ‘growth deals’ — involving companies that expand fast and often disrupt industries — for the first time since 2017.
    Despite a declining pool of investors, Bain said private equity returns are still more attractive than those from the public markets on a five-, 10 and 20-year horizon.

    The timing of a recovery still remains unclear, Bain said, even though there were signs of some improvements toward the end of last year. When the recovery does take effect, disruptive technologies such a generative artificial intelligence are among new areas that hold “great promise,” Bain added.
    Japan, India and Southeast Asia, are among the Asia-Pacific markets being viewed favorably for private equity investment opportunities in the next 12 months, Bain said, citing Preqin’s 2023 investor survey. More

  • in

    As markets soar, should investors look beyond America?

    Every week, a new high. Little wonder a sense of unease is settling over markets. Some 40% of global fund managers think that artificial-intelligence (AI) stocks—a crucial driver of the rally—are already in a bubble, according to Bank of America’s latest monthly survey. Even Wall Street’s most starry-eyed pundits reckon America’s S&P 500 index of leading shares can eke out only minor gains in the remaining nine months of the year. For some, such nervousness portends a crash. But for everyone, it prompts a question: with stock prices having already risen so much, are there any left that offer good value?“Value” stocks are deeply unfashionable, and with good reason. They are defined as shares with prices that are low compared with their underlying assets or earnings (as opposed to “growth” stocks with prices that are high on these measures, yet which promise rapidly rising profits). If that sounds appealing, the returns of recent years have not been. Over the past decade value stocks have lagged behind the broader market and been left in the dust by their growth counterparts (see chart 1). In 2022, as interest rates rose and the prices of speculative assets took a savage beating, the pendulum briefly seemed to be swinging back. But only briefly: the current bull market has once again seen value stocks trounced by the rest.Chart: The EconomistThis losing streak has led many to declare value investing dead. Critics say it struggles to account for the intangible assets and research spending that underpin many of today’s most successful firms. Investing tools make it easy to filter companies based on price-to-value ratios, meaning that potential returns from this approach will probably be arbitraged away fast. The firms left looking cheap, in other words, are cheap for a reason.None of this, though, stops anyone from worrying that the valuations of the stocks leading today’s bull run have become too high to offer stellar future returns. A widely watched metric for this is the cyclically adjusted price-to-earnings (CAPE) ratio devised by Robert Shiller of Yale University, which divides prices by the past decade’s-worth of inflation-adjusted earnings. For America’s S&P 500 index, the CAPE has been higher than it is today only twice: at the peak of the dotcom bubble, and just before the crash of 2022. Even if a crash does not follow, a high CAPE ratio has historically proved to be a strong indicator that poor or even negative long-run real returns lie ahead. You hardly need to be a card-carrying value investor to take this as a cue to look elsewhere.For Victor Haghani of Elm Partners, a fund-management outfit, the response is obvious: look beyond America. In the wider world, valuations are lower (see chart 2). Mr Haghani calculates that, although American stocks attract a much higher aggregate price-to-earnings multiple than those elsewhere, around 40% of their underlying earnings come from overseas. In the rest of the world, some 20% of total earnings derive from America. Put another way, there is a strong degree of crossover in where the profits of the two groups of companies are actually made.Chart: The EconomistDespite this, the values the market assigns to earnings derived from America and elsewhere are wildly different. Mr Haghani’s number-crunching suggests that, to get from earnings to share prices (for both American and non-American stocks), investors are scaling up those coming from America by a factor of more than 40. For earnings coming from the rest of the world the equivalent scaling factor is just ten.This disparity seems to make little sense. It is one thing to suggest that American firms deserve a higher valuation because there is something exceptional about their growth potential. But why should earnings originating from America boost a share’s price so much more than those from elsewhere?Perhaps the stockmarkets of countries outside America (or, equivalently, the earnings coming from these countries) are simply underpriced in relative terms. This is just the sort of mispricing that markets may eventually correct by raising the valuations assigned for non-American firms, lowering those of American firms, or both. What is more, whereas value investing often involves taking concentrated bets on individual companies or sectors, betting on this repricing allows the risk to be spread across most of the world.In fact, even the argument that companies outside America merit their current low valuations because they lack dynamism is threadbare. It is frequently couched in terms of the sectoral composition of each market: America’s is brimming with the disruptive tech firms of tomorrow, while Europe’s, for example, is stuffed with stodgy banks and industrial outfits.But Hugh Gimber of JPMorgan Asset Management pours cold water on the idea that this explains the lower valuations of European firms. His team has split the continent’s companies by sector, analysed the historical multiples by which their earnings have been scaled up to generate their share prices, then compared these with the equivalent multiples for American firms. In most sectors, the European companies’ stocks have suffered from long-run average discounts. Today, though, these discounts are present in every sector—and are much deeper than their long-run averages (see chart 3). Rather than failing to operate in cutting-edge industries, such firms might simply be underpriced.Chart: The EconomistIt is not just in Europe that such potential value trades abound. Mr Gimber points to a range of emerging-market countries that are well placed to profit from global trends, and where valuations are nowhere near as eye-watering as those in America. Examples range from Mexico and Vietnam—benefiting from the “friendshoring” of Western supply chains—to other countries riding the AI wave, such as South Korea and Taiwan.Jens Foehrenbach of Man Group, an asset manager, notes that the Tokyo Stock Exchange has set an explicit target for firms to take actions that will raise their shares’ price-to-book ratios (the firm’s market value divided by its net assets) above 1. Some 42% of the constituents of Japan’s Topix index are yet to reach this, suggesting an obvious bet for those who think they will eventually.A unifying feature of all such markets is that—like any value investment—betting on them involves a leap of faith. The longer America’s stockmarket outperforms the rest, the more it seems like the natural way of things. Maybe companies listed elsewhere look cheaper because they are simply worse. But there are signs that the pricing differentials have grown too large for professional investors to continue tolerating. In March global fund managers told Bank of America’s survey that, month-on-month, they had rotated more of their equity allocations into European and emerging-market stocks than they had done for years. Any that are underpriced might not remain so for long. ■ More

  • in

    Amgen wants in on the booming weight loss drug market — and it’s taking a different approach

    Amgen is among a crowded field of drugmakers racing to develop the next blockbuster weight loss drug — but it’s taking an entirely different approach than its rivals.
    The biotech company is testing a monthly injection that works differently from Wegovy and Zepbound and appears to help patients maintain their weight loss even after they stop taking it.
    Still, more data is needed to see how competitive Amgen will be in the obesity market.

    The Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California.
    Mario Tama | Getty Images

    Amgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug.
    The biotech company is testing an injectable treatment that helps people lose weight differently from the existing injections from Novo Nordisk and Eli Lilly, and other obesity medicines in development. Amgen’s treatment, called MariTide, also appears to help patients keep weight off after they stop taking it.  

    The drugmaker is also testing its drug to be taken once a month or even less frequently, which could offer more convenience than the weekly medicines on the market. 
    It’s too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated.
    Some analysts expect the market could be worth $100 billion by the end of the decade, potentially leaving room for new competitors to enter. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028.
    The available data on Amgen’s injectable drug is promising, but it’s from a small, early-stage clinical trial. The Thousand Oaks, California-based company also is developing an oral medicine and other treatments for obesity, but has disclosed few details about them. 
    Investors and health experts will likely get a better idea of Amgen’s prospects later this year: The drugmaker expects to release initial data from an ongoing mid-stage trial on MariTide, along with phase one data on its obesity pill. 

    It’s also unclear whether Amgen’s treatments will be cheaper than the existing weight loss drugs, which cost around $1,000 per month.
    Wegovy from Novo Nordisk and Zepbound from Eli Lilly lead a new class of obesity treatments that has drawn unrelenting patient demand — and investor interest — despite their hefty price tags and limited insurance coverage. 
    Eli Lilly and Novo Nordisk have also struggled to offer enough supply of their treatments, which could give other companies a chance to win market share.  

    How Amgen’s treatment is different

    Amgen’s drug offers a new twist on weight loss. 
    Much like Wegovy and Zepbound, one part of Amgen’s treatment activates a gut hormone receptor called GLP-1 to help regulate a person’s appetite. 
    But while Zepbound activates a second hormone receptor called GIP, Amgen’s drug blocks it. Wegovy does not target GIP, which suppresses appetite like GLP-1 but may also improve how the body breaks down sugar and fat.
    Amgen’s decision to tamp down rather than boost GIP activity is based on genetics research suggesting that blocking the receptor is linked to lower fat mass and body weight, company executives have said. 

    Some approved and experimental weight loss drugs

    Wegovy from Novo Nordisk: Approved weekly injection that activates GLP-1
    Zepbound from Eli Lilly: Approved weekly injection that activates GLP-1 and GIP
    Saxenda from Novo Nordisk: Approved weekly injection that activates GLP-1
    MariTide from Amgen: Experimental monthly injection that activates GLP-1 and blocks GIP
    Danuglipron from Pfizer: Experimental once-daily pill that activates GLP-1
    VK2735 from Viking Therapeutics: Experimental weekly injection that activates GLP-1 and GIP
    Pemvidutide from Altimmune: Experimental weekly injection that activates GLP-1 and another gut hormone called glucagon
    GSBR-1290 from Structure Therapeutics: Experimental weekly pill that activates GLP-1
    Survodutide from Zealand Pharma, Boehringer Ingelheim: Experimental weekly injection that activates GLP-1 and glucagon

    That appears to contradict how Zepbound works. Eli Lilly’s approach has proven successful: The treatment helped patients with obesity lose up to 22.5% of their weight after 72 weeks in a late-stage trial.
    But Amgen’s MartiTide also was effective in a small, early-stage study. 
    Patients given the highest dose of Amgen’s drug — 420 milligrams — every month lost 14.5% of their body weight on average in just 12 weeks, according to data from the phase one trial published last month in the journal Nature Metabolism. 
    There’s a broader debate among researchers about why both approaches – blocking and activating GIP – are effective at promoting weight loss. 
    One theory is that repeatedly activating the GIP receptor, as Zepbound does, ultimately causes the body to “self-regulate” itself and make sure there isn’t too much GIP activity, said Dr. Caroline Apovian, a director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital.
    That decreases GIP activity overall, which is thought to essentially mimic what Amgen’s drug achieves when it blocks the GIP receptor. But Apovian cautioned that “none of this is proven” and more data is needed.

    The drug could result in longer-lasting weight loss

    Amgen’s treatment may be better at helping people maintain weight loss than competitors, even though patients take it less frequently, early-stage trial data suggests.
    Amgen’s study enrolled 110 patients with obesity but not diabetes. Patients in one group were randomly assigned to receive a single dose of the drug and were followed for 150 days, while a second group was given a dose every four weeks for three months. 

    An obesity patient takes a injection of weight loss medication.
    Joe Buglewicz | The Washington Post | Getty Images

    Patients who received a single shot of the highest dose of MariTide lost up to 8.2% of their body weight after 92 days. That suggests a single injection of the drug has a prolonged weight loss effect, according to the study authors. 
    In the group that received multiple doses of the drug, patients appeared to maintain their maximum weight loss until around two months after their last dose. Their body weight started to slowly return after that. Still, their weight was as much as 11.2% lower five months after they received the last dose. 
    “We think meaningful weight loss is already 5%. If you take Amgen’s drug, lose 14.5%, stop the drug and still have 11.2% weight loss after a few months, that’s significant,” said Dr. Holly Lofton, director of the Weight Management Program at NYU Langone Health and an obesity medicine physician. But she pointed out the need to study the treatment in a larger group of people. 
    The sustained weight loss in Amgen’s study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. Patients in those studies saw their weight rebound sooner after stopping the injections. 

    Once a month or even less frequent dosing 

    The frequency of Amgen’s drug also sets it apart. Those on Wegovy or Zepbound have to take doses weekly, compared with the once-monthly MariTide. 
    Amgen’s trial used monthly dosing in part because patients saw sustained weight loss whether they had a single injection or multiple shots of the company’s drug, according to the study authors. 
    Amgen’s treatment also can stay in the body for much longer than current therapies like Wegovy and Zepbound because it includes a monoclonal antibody, the authors added. 

    An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. 
    Brendan McDermid | Reuters

    Amgen’s MariTide “has that advantage where it’s just going to last a lot longer. Even if you give a high dose, you’re still going to have drug exposure in the body for a month or two months, so that clearly shows you don’t need to take it every week,” William Blair & Company analyst Matt Phipps told CNBC.
    Phipps said people typically don’t want to get injections often, so some patients could prefer a monthly shot like Amgen’s MariTide for a disease that will likely require chronic treatment. 
    But he noted that a patient’s choice may also depend on whether the level of weight loss and side effects of Amgen’s drug end up being on par with those of the existing weekly injections. 
    Amgen’s ongoing phase two trial is exploring whether patients can take its drug even less frequently than once a month. 

    Phase two trial will bring more clarity

    Amgen’s longer-term phase two study on nearly 600 patients will provide more clarity on how competitive MariTide will be against Wegovy and Zepbound. The company is exploring which dose strength and schedule is best for patients. It expects to release initial trial results later this year. 
    Some analysts have said the phase two trial could help address several questions, including how well patients tolerate the treatment at different dose regimens.
    The 52-week study is testing 11 different patient groups at a variety of dosing levels and regimens. That includes starting some patients at a lower dose of a drug and gradually increasing it until they reach a higher target dose. 
    That dose escalation could help reduce side effects that some patients experienced after taking their first dose of MariTide in the phase one trial, according to Phipps.
    In that trial, the safety and side effects of Amgen’s drug were similar to other GLP-1 medications. Nausea and vomiting were the most commonly reported side effects, and typically lasted for about 72 hours. 
    Four out of eight patients in a group receiving the highest dose of the treatment withdrew before getting a second shot due to mild gastrointestinal issues, according to the study. But no other patients stopped taking the drug due to adverse events across any of the different dosing groups, Amgen Chief Medical Officer Paul Burton said during a conference earlier this month. 
    “It’s a little early to jump to the conclusion that the drug won’t be tolerated by patients based on this phase one data,” William Blair & Company’s Phipps said.
    Another part of Amgen’s phase two trial will also examine weight loss beyond 52 weeks, which will provide a clearer picture of how long the drug is effective.

    Don’t miss these stories from CNBC PRO: More

  • in

    Two fresh ways to play the weight loss and megacap tech hype

    A major exchange-traded fund provider is going deep on two popular plays: megacap tech and weight loss drug stocks.
    In health care, Roundhill Investments is getting ready to launch a fund that focuses on the companies behind GLP-1 drugs. Dave Mazza, the firm’s chief strategy officer, expects to have more information on the fund’s debut in May.

    “It’s going to be important to kind of keep an eye on this space,” Mazza told CNBC’s “ETF Edge” this week. “We’re going to see some rapid advancements in drugs. We’re already seeing rapid advancements of those leaders launching new drugs and new opportunities in the market.”
    This wouldn’t be Roundhill’s first new product this year. The firm launched leveraged and inverse exchange-traded funds three weeks ago that track widely held tech stocks. They are the Roundhill Daily 2X Long Magnificent Seven ETF (MAGX) and the Roundhill Daily Inverse Magnificent Seven ETF (MAGQ).
    MAGX is designed to profit from “Magnificent Seven” gains, which comprises Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia and Tesla. Meanwhile, MAGQ gives investors a way to bet negatively on the group.
    “These are tools that can be used for traders who have short-term views on the Magnificent Seven — both positive and negative to express that view,” said Mazza. “If you’re bullish, maybe look to that two-times amplified exposure with MAGX. Or, if you want to hedge your position or take an outright bearish view on a short-term basis, there’s MAGQ.”
    Both funds reset their performances each day. So, they’re considered risky choices for investors, according to Mazza.

    “You need to be able to view your positions on a daily basis. You can hold it for more than a day, but you need to be able to reassess: ‘Is this the right trade for me to be in?'” Mazza said. “They’re not intended to be held for longer time periods.”

    ‘You’re going to strike out a lot’

    VettaFi’s Todd Rosenbluth cautions leveraged and inverse ETFs may not be suitable for every investor due to volatility.
    “You really need to go in with your eyes open and understand that every day these could perform really well or really poorly,” the firm’s head of research said. “I like to think of leveraged and inverse ETFs as in playing baseball swinging for the fences. You’re going to hit a couple of home runs. You’re going to strike out a lot.”
    Since their debuts on Feb. 29, the Roundhill Daily 2X Long Magnificent Seven ETF is up almost 7%, while the firm’s Daily Inverse Magnificent Seven ETF is down nearly 4%.
    Disclaimer More

  • in

    Here’s how much people are willing to spend on weight loss drugs, according to a new survey

    Americans can’t seem to get enough of weight loss drugs despite their limited insurance coverage and roughly $1,000 monthly price tags before discounts. 
    But some patients are willing to pay more out of pocket for those treatments than others — and it’s strongly correlated to their annual income.
    That’s according to a recent survey from Evercore ISI that focused on GLP-1s, which include Novo Nordisk’s weight loss injection Wegovy and diabetes counterpart Ozempic.

    Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. 
    Hollie Adams | Reuters

    Demand for weight loss drugs is booming in the U.S. despite their limited insurance coverage and roughly $1,000 monthly price tags before discounts. 
    But some patients are willing to pay more out of pocket for those treatments than others — and that desire is strongly correlated to their annual income.

    That’s according to a recent survey from Evercore ISI focused on GLP-1s, a new class of medications used to treat Type 2 diabetes and obesity. Between Jan. 24 and Feb. 20, the firm surveyed more than 600 participants who are currently taking a GLP-1, considering the therapy or have taken it in the past but no longer do. 
    The findings on how much patients are willing to spend underscore concerns about equity in access to the breakthrough drugs while insurance coverage is sparse.
    GLP-1s include Novo Nordisk’s blockbuster weight loss injection Wegovy and diabetes counterpart Ozempic, along with Eli Lilly’s popular weight loss treatment Zepbound and diabetes injection Mounjaro. 
    A monthly package of a GLP-1 costs between $900 and $1,350 before insurance and other rebates. Both Novo Nordisk and Eli Lilly have savings programs that aim to reduce out-of-pocket costs for weight loss drugs, regardless of whether a patient has commercial insurance coverage. 
    The majority — nearly 60% — of people surveyed with annual incomes of more than $250,000 said the maximum price they are willing to pay out of pocket for a GLP-1 is more than $300 per month. 

    Only about 4% of people with annual incomes of less than $75,000 said the same thing. Of that group, 64% said the maximum price they are willing to pay out of pocket for a GLP-1 is $50 per month or less. 

    The maximum people currently on a GLP-1 said they are willing to pay out of pocket per month was roughly in line with what they actually paid for treatment, according to the survey. The highest price respondents would accept paying skewed lower among those who used to take a GLP-1 or are thinking of taking the drug. 
    More than half of people currently taking a GLP-1 said they are paying a monthly price of $50 or less out of pocket. Nearly 75% of those who used to take one of the drugs said they spent the same amount. 
    A small share of both groups paid more than $750 out of pocket per month for a GLP-1.

    The survey also asked respondents how long they stayed on the drugs.
    Notably, more than 80% of those who used to take a treatment were only on a therapy for 12 months or less. Some people stopped due to cost, while others stopped a treatment because they hit their weight loss goal or experienced side effects.
    That premature stoppage by some patients is one concern of certain insurers hesitant to cover them.
    Still, nearly half of people who are currently taking GLP-1s said they intend to stay on the drugs permanently. Only 10% of those thinking of taking a treatment said the same thing. Of that group, more than 70% said they intend to stay on a GLP-1 until they reach their weight loss goal.
    The survey also asked participants whether they would restart taking a GLP-1 if they regain weight after stopping the drug. The majority of patients across all groups — those currently on a GLP-1, thinking of it, or who used to take one — said “yes.” 

    Among those who used to take a GLP-1, 42% said they gained “some” weight back after stopping treatment. Around 13% said they gained most of it back, while 23% said they gained all of it back. Another 23% said they remained at a lower weight after stopping the drug.
    That weight regain is consistent with what has been observed in some clinical trials on drugs such as Wegovy and Zepbound.
    Another part of the survey asked participants about whether taking a GLP-1 affected their eating and drinking habits. 
    More than 70% of respondents reporting eating less when taking a GLP-1, regardless of whether they have pre-existing conditions. That refers to other health problems, such as diabetes, asthma or high blood pressure.
    The survey finding is no surprise: GLP-1s work by mimicking a hormone produced in the gut to suppress a person’s appetite and regulate blood sugar. Some treatments, such as Zepbound, mimic more than one gut hormone.

    More than half of those without preexisting conditions said they drank less alcohol when taking a GLP-1. Around 27% said the treatment had no effect on their alcohol consumption, while 22% said they abstain from drinking. 
    A greater share — 51% — of those with preexisting conditions said they abstain from alcohol. The remainder said they consumed less alcohol when taking a GLP-1. 
    Several studies have demonstrated that certain GLP-1s curb alcohol intake in rodents and monkeys. But more research is needed in humans.

    Don’t miss these stories from CNBC PRO:

    — CNBC’s Gabriel Cortés contributed to this report More

  • in

    ‘Gray divorce’ has doubled since the ’90s — and the financial risk is high for women

    Women and Wealth Events
    Your Money

    The rate of divorce among Americans age 50 and older has doubled since the 1990s. It has tripled for adults over 65 years old.
    So-called “gray divorce” puts women at high financial risk.
    There are steps women can take now to protect themselves.

    Laylabird | E+ | Getty Images

    Breaking up in old age can be costly, especially for women.
    The rate of “gray divorce” — a term that describes divorce at age 50 and older — doubled from 1990 to 2019, according to a 2022 study published in The Journals of Gerontology. It tripled for adults over age 65.

    In 1970, about 8% of Americans who divorced were age 50 and older. By 2019, that share had jumped to an “astounding” 36%, the study found.
    About 1 in 10 people — 9% — who divorced in 2019 were at least 65 years old.
    Meanwhile, rates of divorce have declined among younger adults, according to Susan Brown and I-Fen Lin, sociology professors at Bowling Green State University who authored the analysis.

    The ‘chronic economic strain’ of gray divorce

    In heterosexual relationships, gray divorce typically “has more negative implications for women than for men,” said Kamila Elliott, a certified financial planner and co-founder of Collective Wealth Partners, based in Atlanta.
    Studies suggest women’s household income generally drops between 23% and 40% in the year after a divorce.

    The economic effects are “less severe” for men, with some studies showing their income may even rise after a breakup, according to Laura Tach and Alicia Eads, sociology professors at Cornell University and the University of Toronto, respectively. The duo have co-authored several papers on the topic.

    More from Women and Wealth:

    Here’s a look at more coverage in CNBC’s Women & Wealth special report, where we explore ways women can increase income, save and make the most of opportunities.

    Those financial disparities seem to be more muted for younger generations of women due to a greater likelihood of them working relative to older cohorts, experts said. Many older adults who divorce today adhered to the traditional notion of a man as a household’s sole breadwinner, they said.
    “We’re seeing women in divorce today who are of the generation where they just didn’t work their entire life,” said Natalie Colley, a CFP based in New York and senior lead advisor at Francis Financial.
    Women also tend to earn lower incomes than men due to a persistent wage gap; they tend to have less savings, and near-retirees who are divorcing don’t have much time to make up the difference. Divorced women can claim a Social Security benefit based on their own earnings or a former spouse’s earnings history, but the latter option is generally worth only up to half of an ex’s benefit.

    Remarrying or cohabitating generally helps bolster one’s finances via pooling of resources. But women who undergo gray divorce are less likely to do so than men: Only 22% of women re-partnered in the decade after gray divorce versus 37% of men, putting them at “sustained economic disadvantage into old age,” according to a separate paper by Brown and Lin.
    Altogether, women’s standard of living declined by 45% following a gray divorce, while the drop for men was less severe, at 21%, Brown and Lin wrote.
    These negative economic outcomes persisted over time, “indicating that gray divorce operates as a chronic economic strain,” they said.
    Poverty levels among women old enough to qualify for Social Security retirement benefits are almost twice as high for women who divorced after age 50 as those who divorced before age 50, Brown and Lin found; the same isn’t true for men.

    How women can protect themselves financially

    Courtneyk | E+ | Getty Images

    Here are some steps women can take to protect against the financial pitfalls of a potential future divorce, according to financial advisors.
    Get active in your household finances. “Women should take a very active role in their household finances,” said Elliott, a member of CNBC’s Advisor Council.
    Women shouldn’t get to a point where they’re unaware of their household’s spending, savings, and mortgage payments and interest rates, for example, she said. Such information could come as a surprise upon divorce, and women may learn they’re not financially well-protected.
    Additionally, being unengaged from financial decision-making may mean they’re ill-equipped to handle their own finances if they become single, Colley said.
    “I can’t tell you how many times I’ve met couples where the woman had no idea what the husband was doing financially,” Elliott said.
    Have access to your own money. Many couples commingle their financial accounts. Many women may also be authorized users of credit cards instead of primary owners, Elliott said.
    But women should ensure they have access to their own funds so their spouse can’t shut off the financial spigot if a relationship sours, Elliott said.

    Additionally, women should consider investing or saving in their own retirement account, she added.
    Retirement savers generally need earned income to open and contribute to an individual retirement account; however, women who don’t work can open a “spousal IRA” based on their spouse’s income. (You must be married and file a joint tax return to open one.)
    Be strategic about claiming Social Security. Social Security is an important source of guaranteed income in retirement, especially for women.
    The sequence of claiming benefits can be important for married couples and can help women hedge against divorce (or widowhood) later, Colley said.
    For example, let’s say a husband is eligible for a larger Social Security benefit relative to his female spouse. He can defer claiming benefits to age 70, thereby maximizing his lifetime monthly benefit.
    That increases the monthly benefit his wife could receive upon divorce or widowhood, and helps maximize a woman’s cash flow in such circumstances, Colley said.
    Save some alimony. If a woman receives alimony after a divorce, she should aim to save some of it, instead of spending it all, Elliott said. That’s because alimony generally only lasts for a certain period — and women must make it last, she said.

    I can’t tell you how many times I’ve met couples where the woman had no idea what the husband was doing financially.

    Kamila Elliott
    certified financial planner and co-founder of Collective Wealth Partners

    “Just because you get alimony, it’s not business as usual” relative to spending levels, she said. “You probably need to reassess your lifestyle.”
    Consider a prenuptial or postnuptial agreement. Couples can also consider a prenuptial agreement or postnuptial agreement that contains provisions to protect a woman financially if she leaves the workforce to care for their children, for example, Colley said.
    Doing so generally permanently dents the caregiver’s earning power, and a legal agreement can help insulate against that financial risk, she added. For example, perhaps it stipulates the woman gets a guaranteed stream of income for a certain number of years if the marriage dissolves, Colley said. She recommends working with an attorney who specializes in such legal documents. More

  • in

    What investors should know about the U.S. easing vehicle emissions rules

    New Biden administration standards for tailpipe emissions are expected to be a win for legacy automakers such as GM, Ford and Stellantis.
    The new regulations come as adoption of electric vehicles in the U.S. has been slower than expected.
    Tesla and environmental groups criticized the standards, which may be designed in part to help Biden with key constituencies in the presidential election.

    President Joe Biden speaks at the United Auto Workers political convention at the Marriott Marquis in Washington, D.C., Jan. 24, 2024.
    Saul Loeb | AFP | Getty Images

    DETROIT — The Biden administration’s decision to ease its timeline for all-electric vehicle adoption and give automakers more ways to meet new tailpipe emissions standards is expected to be a win for legacy automakers.
    The new Environmental Protection Agency rules released Wednesday aim to cut tailpipe emissions by 49% between model years 2027 and 2032. The EPA set a target for EVs to make up at least 35% of new vehicle sales by 2032.

    The standards are less ambitious than proposed rules released last year, which targeted a 56% reduction in emissions by 2032 and called for EVs to represent 67% of new vehicles by that year.
    The lower expectation for EV adoption comes amid slower-than-expected sales of the vehicles, which can cost tens of thousands of dollars more than their traditional gas counterparts.
    The EPA’s new strategy for cutting tailpipe emissions doesn’t focus only on EVs. It took into account more efficient gasoline engines, hybrids and plug-in hybrid electric vehicles.
    The EPA’s percentage targets for EV adoption are not mandates but expectations for how automakers could meet the emissions regulations. The target range for the share of EV sales in the market in 2032 is between 35% and 56%.
    The EPA said the standards will avoid more than 7 billion tons of carbon emissions and provide nearly $100 billion of annual net benefits to society. It said those include $13 billion of annual public health benefits due to improved air quality, along with $62 billion in reduced annual fuel costs and maintenance and repair costs for drivers.

    Here are some key takeaways about what the new guidelines mean for automakers, investors and the environment.

    A win for Detroit

    Automotive officials and Wall Street analysts are touting the altered rules as a major win for legacy automakers, specifically the traditional Detroit automakers General Motors, Ford Motor and Chrysler parent Stellantis, which largely rely on big SUVs and trucks to make profits.
    “We view this development as positive for traditional US automakers, since the new rules put less pressure on them to ramp up EV production in the near term, and could even potentially enable them to reduce further EV capex and R&D,” Deutsche Bank analyst Emmanuel Rosner said Thursday in an investor note.

    President Joe Biden, with General Motors CEO Mary Barra, looks at a Chevrolet Silverado electric vehicle as he tours the 2022 North American International Auto Show at Huntington Place Convention Center in Detroit, Michigan, on Sept. 14, 2022. Biden is visiting the auto show to highlight electric vehicle manufacturing.
    Mandel Ngan | Afp | Getty Images

    John Bozzella, president and CEO of the Alliance for Automotive Innovation, a lobbying group that represents most automakers in the U.S., agreed.
    “Moderating the pace of EV adoption in 2027, 2028, 2029 and 2030 was the right call because it prioritizes more reasonable electrification targets in the next few (very critical) years of the EV transition,” he said.
    The new rules also are a victory for the Detroit-based United Auto Workers union, which has raised concerns about how the transition from internal combustion engines to EVs could affect jobs.
    “By taking seriously the concerns of workers and communities, the EPA has created a more feasible emissions rule that protects workers building [internal combustion engine] vehicles, while providing a path forward for automakers to implement the full range of automotive technologies to reduce emissions,” the UAW said in a statement.
    Stocks for the Detroit automakers, as well as others such as U.S. hybrid leader Toyota Motor, closed higher Wednesday following the announcement.

    Tesla, some green groups unhappy

    While the new standards sparked relief in Detroit, others weren’t too pleased.
    The new rule “falls far short of what is needed to protect public health and our planet. EPA is giving automakers a pass to continue producing polluting vehicles,” said Chelsea Hodgkins, senior policy advocate at left-leaning consumer rights group Public Citizen.
    Martin Viecha, vice president of investor relations for the biggest U.S. EV maker, Tesla, agreed in a post on X: “Unfortunately, people use plug-in hybrids mainly as gas cars, which means their CO2 emissions are far worse than official EPA or WLTP ratings suggest.”
    “Just like officially rated energy consumption of EVs has been getting closer and closer to reality, same should be done for plug-in hybrids,” he added.
    Environmental group Sierra Club, which has condemned automakers such as Toyota for their reliance on hybrids, broke with past statements and hailed the standards. The organization, which endorsed President Joe Biden for reelection, said the new rules are “one of the most significant actions his administration can take on climate change.”

    Political implications

    Several experts and Wall Street analysts were quick to point out that the new standards could help Biden with some groups in his reelection campaign.
    “We surmise this slight leniency appeases to lobbying on behalf of automakers — or more pointedly, the auto unions — which have understandably viewed the aggressive efforts (e.g., the IRA bill turned law) by the Biden administration to ‘electrify’ the auto industry as a threat to their jobs in conventional auto manufacturing plants,” Loop Capital analyst Chris Kapsch said in an investor note.
    Morgan Stanley analyst Adam Jonas agreed in a separate note: “The delay and flexibility baked into the new timeline could be part of an effort to appease the UAW, a key Democratic constituency historically concerned about the rise of EVs.”
    The move could help the president with the UAW, which endorsed Biden for reelection in January. It could also be designed to boost him in Michigan — home of GM, Ford and many other suppliers — which is expected to play a pivotal role as a swing state in this year’s presidential election.

    Not over yet

    The tailpipe emissions regulations are only one part of the federal government’s policies that aim to boost the efficiency of vehicles.
    Automakers are still awaiting the “Corporate Average Fuel Economy,” or CAFE, standards from the National Highway Traffic Safety Administration, a part of the Department of Transportation, for 2027 to 2032 model-year vehicles.
    CAFE standards set out to regulate how far vehicles must travel on a gallon of fuel. NHTSA in 2023 proposed an industry fleet-wide average of approximately 58 miles per gallon for passenger cars and light trucks in model year 2032, by increasing fuel economy by 2% per year for passenger cars and by 4% annually for light trucks.
    The CAFE standards are expected to be finalized later this year.
    There’s also the California Air Resources Board, which can set its own standards for emissions and fuel economy – a power former President Donald Trump attempted to take away.
    For years, automakers such as GM have argued there should be one national standard for fuel economy and greenhouse gas emissions to help them plan and make it easier to comply.
    “While we review the details, we encourage continued coordination across the U.S. federal government and with the California Air Resources Board to ensure the auto industry can successfully transition to electrification,” GM said in a statement.
    — CNBC’s Michael Bloom contributed to this report.

    Don’t miss these stories from CNBC PRO: More

  • in

    Anthropic is lining up a new slate of investors, but the AI startup has ruled out Saudi Arabia

    Sovereign wealth funds and other investors are jostling to buy into an Anthropic stake worth more than $1 billion.
    The AI startup has ruled out taking any Saudi money over national security concerns, sources say, despite the kingdom’s ambitions to get in on the AI boom.
    Existing Anthropic stakeholders, including Amazon and Google, are not expected to increase their holdings in this round.

    Deep-pocketed, sovereign wealth funds are among the investors clamoring to get a stake in Anthropic, the red-hot artificial intelligence startup that’s taking on OpenAI. One country that’s being left out: Saudi Arabia.
    As bankers line up a group of potential new Anthropic backers, the company has ruled out taking money from the Saudis, according to people familiar with the matter. Anthropic executives cited national security, one of the sources told CNBC. 

    The stake in Anthropic is for sale because it belongs to FTX, the failed cryptocurrency exchange started by Sam Bankman-Fried, and is being unloaded as part of the company’s bankruptcy proceedings. FTX bought the shares three years ago for $500 million. The 8% stake is now worth more than $1 billion due to the recent boom in AI.
    Proceeds from the sale will be used to repay FTX customers. The transaction is ongoing and is on track to wrap up in the next couple weeks, said people with knowledge of the talks who asked not to be named because the negotiations are private.
    The class B shares, which don’t come with voting rights, are being sold at Anthropic’s last valuation of $18.4 billion, sources said. Anthropic has raised roughly $7 billion in the last few years from tech giants like Amazon, Alphabet and Salesforce. Its large language model competes with OpenAI’s ChatGPT. 
    Anthropic founders Dario and Daniela Amodei have the right to challenge any potential investors, according to the sources. However, they are not involved in the current fundraising process, or in the discussions with potential investors in FTX’s stake. The founders were introduced to Bankman-Fried through “effective altruism,” a philosophy that involves making as much money as possible to give it all away.

    Saudi Crown Prince and Prime Minister Mohammed bin Salman meets U.S. Secretary of State Antony Blinken (not pictured), in Jeddah, Saudi Arabia March 20, 2024. 
    Evelyn Hockstein | Reuters

    While Anthropic’s founders told bankers they wouldn’t accept Saudi money, they don’t plan to challenge funding from other sovereign wealth funds, including United Arab Emirates fund Mubadala. The UAE-based firm is actively looking at investing, according to one of the sources.

    The potential buyers of FTX’s shares comprise a syndicate of new investors for Anthropic, a source said, meaning Amazon and Alphabet would not be involved. Part of FTX’s stake is being shopped around through special purpose vehicles, or SPV, which allows multiple investors to pool capital. SPVs have been emailing venture firms to solicit participation, three sources said. Investment bank Perella Weinberg is handling the sale on behalf of FTX.
    Representatives from Anthropic and Perella Weinberg declined to comment on the sale. Mubadala and Saudi Arabia’s Public Investment Fund, or PIF, didn’t immediately respond to a request for comment.
    The PIF, Saudi Arabia’s sovereign wealth fund, has more than $900 billion in assets and has been plowing capital into technology to diversify the nation’s revenue away from oil. The fund is in talks with venture firm Andreessen Horowitz to create a $40 billion fund to invest in AI, two sources with knowledge of the matter told CNBC. The discussions were first reported by the New York Times. 
    Saudi Crown Prince Mohammed bin Salman’s ambitious “Vision 2030 Initiative” has looked to modernize the economy and strengthen ties in global finance. The PIF has investments in companies including Uber, while also funding the LIV golf league and spending heavily in professional soccer and tennis.
    Anthropic’s national security concerns regarding Saudi Arabia could be over dual-use technology — software or tech that can be used for both civilian and military applications. That’s an area of notable focus for the Committee on Foreign Investment in the United States (CFIUS), which can block foreign investments from particular sources in certain areas. Saudi Arabia has also been warming to China.
    The kingdom’s human rights record remains a major problem for some Western partners. The most notable case in recent years was the alleged killing of Washington Post journalist Jamal Khashoggi in 2018, an event that triggered international backlash in the business community.
    In November, Bankman-Fried was convicted of seven criminal counts tied to the collapse of FTX. His sentencing is scheduled for next week, and prosecutors are recommending a sentence of 40 to 50 years.
    WATCH: Prosecutors recommend a 40-50 year prison sentence for SBF More